Fig. 1: The association of PD-L1 expression and TMB with pathologic response to sintilimab. | npj Precision Oncology

Fig. 1: The association of PD-L1 expression and TMB with pathologic response to sintilimab.

From: Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade

Fig. 1: The association of PD-L1 expression and TMB with pathologic response to sintilimab.The alternative text for this image may have been generated using AI.

a The correlation between pathological regression and TPS (Spearman’s correlation coefficient R = 0.40, p = 0.04). b Comparison of TPS in MPR and Non-MPR group (p = 0.07, Mann–Whitney U test). c, d Distribution of MPR and Non-MPR patients in groups with high (≥50%) or low TPS ( < 50%) (p = 0.02, Fisher’s exact test). e The correlation between pathological regression and TMB (Spearman’s correlation coefficient R = 0.32, p = 0.15). f Comparison of TMB in MPR and Non-MPR group (p = 0.05, Mann–Whitney U Test). g, h Distribution of MPR and Non-MPR patients in groups with high (>12 muts/mb) or low TMB ( < 12 muts/mb) (p = 0.01, Fisher’s exact test).

Back to article page